Valuation: ARS Pharmaceuticals, Inc.

Market Cap 850M 744M 687M 642M 1.21B 80.37B 1.24B 8.27B 3.19B 39.65B 3.19B 3.12B 138B P/E 2026 *
-4.85x
P/E 2027 * -9.56x
Enterprise Value 850M 744M 687M 642M 1.21B 80.37B 1.24B 8.27B 3.19B 39.65B 3.19B 3.12B 138B EV / Sales 2026 *
6x
EV / Sales 2027 * 3.34x
Free-Float
83.79%
Yield 2026 *
-
Yield 2027 * -
1 day+0.23%
1 week-14.23%
Current month-5.62%
1 month-5.62%
3 months+6.07%
6 months-26.96%
Current year-26.52%
1 week 7.5
Extreme 7.5001
10.87
1 month 7.5
Extreme 7.5001
10.87
Current year 7.03
Extreme 7.03
13.15
1 year 6.66
Extreme 6.66
18.63
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 57 2018-08-31
Chief Tech/Sci/R&D Officer - 2015-08-04
Chief Executive Officer 60 2018-08-31
Director TitleAgeSince
Director/Board Member 60 2015-08-04
Chairman 56 2022-11-07
Director/Board Member 55 2021-07-31
Date Insider Type Main position Quantity % Market Cap.
Jun. 23Free

Director

30,000 0.0302%
Jun. 23Free

Director

30,000 0.0302%
Jun. 23Free

Director

30,000 0.0302%
Change 5-day change 1-year change 3-year change Capi.($)
+0.23%-14.23%-52.97%+29.50% 850M
+0.95%+5.63%-3.68%+2.02% 46.62B
+5.79%+16.17%+421.86%+634.63% 40.95B
+1.12%+15.18%+22.74%-12.71% 32.26B
+3.61%+6.69%+20.23%+62.38% 32.24B
+8.02%+6.35%+17.67%+34.73% 25.53B
+1.13%+15.66% - - 16.38B
+1.45%+17.35%+72.11%+127.60% 15.27B
+0.12%+4.63%+12.94%+17.37% 13.61B
-0.60%+6.32%+102.74%+96.28% 13.34B
Average +2.18%+9.00%+68.18%+110.20% 23.7B
Weighted average by Cap. +2.84%+11.49%+97.63%+145.31%

Financials

2026 *2027 *
Net sales 142M 124M 115M 107M 201M 13.4B 206M 1.38B 532M 6.61B 532M 521M 22.96B 255M 223M 206M 192M 362M 24.08B 370M 2.48B 957M 11.88B 957M 936M 41.25B
Net income -176M -154M -142M -133M -250M -16.66B -256M -1.71B -662M -8.22B -662M -647M -28.54B -90.88M -79.57M -73.46M -68.6M -129M -8.59B -132M -884M -341M -4.24B -341M -334M -14.72B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
157
Date Price Change Volume
26-06-29 $8.560 +0.23% 1,407,645
26-06-26 $8.540 +6.48% 5,015,475
26-06-25 $8.020 -23.91% 8,082,059
26-06-24 $10.54 +2.53% 1,940,618
26-06-23 $10.28 +3.01% 1,304,901
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.560USD
Average target price
29.25USD
Spread / Average Target
+241.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock